Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
Aug 2022 | From Akero Therapeutics
Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health
Aug 2022 | From Akero Therapeutics
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
![PSB-Image-Pipeline](https://akerotx.com/wp-content/uploads/2021/08/PSB-Image-Pipeline.jpg)
![PSB-Image-Pipeline](https://akerotx.com/wp-content/uploads/2021/08/PSB-Image-Pipeline.jpg)